PENBRAYA Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The PENBRAYA market research report is one of a series of new reports that provides PENBRAYA market statistics, including PENBRAYA industry global market size, regional shares, competitors with a PENBRAYA market share, detailed PENBRAYA market segments, market trends and opportunities, and any further data you may need to thrive in the PENBRAYA industry. This PENBRAYA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the expansion of biopharma pipelines, improving delivery mechanisms, policy support for biosimilars, expansion of oncology biologics, and expanded use of real-world evidence (RWE). Major trends in the forecast period include regulatory harmonization, advances in monoclonal antibodies, proliferation of cell and gene therapies, advancements in bioprocessing, and proactive pharmacovigilance.

The growing prevalence of meningococcal meningitis is expected to drive the expansion of the PENBRAYA market in the future. Meningococcal meningitis is a serious and potentially fatal infection affecting the protective membranes (meninges) surrounding the brain and spinal cord, caused by the bacterium Neisseria meningitidis (meningococcus). The rise in meningococcal cases can be attributed to factors such as the emergence of new bacterial strains, increased population density, insufficient vaccination coverage, and the growing volume of global travel, which facilitates the spread of the infection. PENBRAYA plays a crucial role in preventing this disease, providing advanced protection and ensuring preparedness for rapid responses to meningococcal outbreaks. For example, a report from the Centers for Disease Control and Prevention (CDC) in April 2024 highlighted a 75% increase in reported cases of meningococcal meningitis in the U.S. compared to the same period in 2023, with 143 cases recorded. This surge in cases is expected to further drive the demand for PENBRAYA.

The growth of the PENBRAYA market is also being fueled by the rise in vaccination programs. These programs are organized efforts to vaccinate populations in order to prevent the spread of infectious diseases. As the incidence of these diseases increases, so does the push for expanded vaccination coverage, especially in high-risk populations and regions with limited access to healthcare. Governments, healthcare organizations, and global health initiatives are actively promoting vaccines such as PENBRAYA in routine immunization schedules, particularly in settings with increased risk, such as college campuses and military environments. A CDC report in November 2024 noted a slight increase in the influenza vaccination rate among adults aged 18 and older, from 33.8% in 2023 to 34.7% in 2024, highlighting the growing acceptance and implementation of vaccination efforts that are likely to support the broader adoption of PENBRAYA.

The PENBRAYA market is experiencing growth as a result of the regulatory approval of its treatment options, which broadens their application and enhances public health measures against meningococcal disease. Regulatory approvals refer to the official authorization given by government agencies for a drug or treatment to be marketed and used. In October 2023, Pfizer received approval from the U.S. Food and Drug Administration (FDA) for PENBRAYA, making it the first and only pentavalent vaccine designed to prevent invasive meningococcal disease caused by the five most common serogroups: A, B, C, W, and Y. Approved for adolescents and young adults aged 10 to 25 years, PENBRAYA provides broad protection against these five major serogroups, significantly reducing the risk of severe disease or death. This vaccine simplifies the vaccination schedule by combining elements of Trumenba and Nimenrix, potentially reducing the number of doses required. Clinical trials have demonstrated that PENBRAYA offers comparable immunogenicity to existing vaccines, while maintaining a robust safety profile.

The key company operating in the penbraya market is Pfizer Inc.

North America was the largest region in the PENBRAYA market in 2024. The regions covered in PENBRAYA report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the PENBRAYA market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

PENBRAYA is a vaccine developed to safeguard against invasive meningococcal disease, which is caused by the Neisseria meningitidis bacteria. It targets five major serogroups - A, B, C, W, and Y - that are primarily responsible for meningococcal infections. This vaccine is the first of its kind to offer extensive protection against these five serogroups, potentially streamlining vaccination schedules and enhancing coverage among adolescents and young adults.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

PENBRAYA is available in different formulations, including oral tablets or capsules and injectable forms. Tablets and capsules are commonly used for oral medication delivery, while injectables are typically administered for various clinical needs. The vaccine is indicated for a range of uses such as meningococcal disease prevention, for individuals at high risk, routine vaccination, travel and occupational exposures, as well as outbreak control. It is distributed through wholesalers, retailers, and online platforms, and serves various end users, including healthcare providers, patients, pharmacies, and retailers.

The PENBRAYA market consists of sales of PENBRAYA 10% EC (emulsifiable concentrate) and PENBRAYA 25% WP (wettable powder). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.